Citigroup
ADIL

Citigroup’s Adial Pharmaceuticals ADIL Stock Holding History

Citigroup’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Hold
0
– – – 5901
2025
Q4 		– Hold
0
– – – 6014
2025
Q3 		– Sell
-159
Closed -$1.2K – 6053
2025
Q2 		$1.2K Buy
+159
New +$2.4K ﹤0.01% 5396

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Citigroup's ADIL Position: Q1 2026 in Review

Citigroup held its Adial Pharmaceuticals (ADIL) position steady in Q1 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5901.

Citigroup first reported a position in ADIL in Q2 2025 and has held it in 1 quarter since. The position peaked at $1.2K in Q2 2025. 14 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

  • Citigroup held 0 shares of Adial Pharmaceuticals worth $0 as of Q1 2026.
  • Citigroup left its Adial Pharmaceuticals share count unchanged in Q1 2026.
  • Adial Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5901 holding.
  • Citigroup first reported a position in Adial Pharmaceuticals in Q2 2025 and has held it in 1 quarter since.
  • Citigroup's Adial Pharmaceuticals position peaked at $1.2K in Q2 2025.
  • 14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.